Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib and Pembrolizumab in Metastatic Breast Cancer or Melanoma (SELENA)
NCT06545682Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2024
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib and pembrolizumab in melanoma, triple-negative breast cancer (TNBC) and brain metastases (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
alpelisibpembrolizumab
03
Conditions
melanomatriple-negative breast cancer (TNBC)brain metastases
Beyond the preview
Go deeper on NCT06545682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545682.